Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.

Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W.

Circ Res. 2015 Mar 27;116(7):1133-42. doi: 10.1161/CIRCRESAHA.116.305485. Epub 2015 Jan 14. Erratum in: Circ Res. 2015 Jul 17;117(3):e40.

2.

In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Zhao Y, Black AS, Bonnet DJ, Maryanoff BE, Curtiss LK, Leman LJ, Ghadiri MR.

J Lipid Res. 2014 Oct;55(10):2053-63. doi: 10.1194/jlr.M049262. Epub 2014 Jun 29.

3.

Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Hime NJ, Black AS, Bonnet DJ, Curtiss LK.

J Lipid Res. 2014 Sep;55(9):1864-75. doi: 10.1194/jlr.M046318. Epub 2014 May 12.

4.

Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.

Zhao Y, Imura T, Leman LJ, Curtiss LK, Maryanoff BE, Ghadiri MR.

J Am Chem Soc. 2013 Sep 11;135(36):13414-24. doi: 10.1021/ja404714a. Epub 2013 Aug 26.

5.

Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.

van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, Mahmud E, Dennis E, Curtiss LK, Witztum JL, Wasserman BA, Otsuka F, Virmani R, Tsimikas S.

J Lipid Res. 2012 Dec;53(12):2773-90. doi: 10.1194/jlr.P030890. Epub 2012 Sep 11.

6.

Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists.

Curtiss LK, Black AS, Bonnet DJ, Tobias PS.

J Lipid Res. 2012 Oct;53(10):2126-32. doi: 10.1194/jlr.M028431. Epub 2012 Jul 20.

7.

The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice.

Richards MR, Black AS, Bonnet DJ, Barish GD, Woo CW, Tabas I, Curtiss LK, Tobias PS.

Innate Immun. 2013 Feb;19(1):20-9. doi: 10.1177/1753425912447130. Epub 2012 May 25.

8.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N.

J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.

9.

MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through Toll-like receptors 2 and 4.

Owens AP 3rd, Rateri DL, Howatt DA, Moore KJ, Tobias PS, Curtiss LK, Lu H, Cassis LA, Daugherty A.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2813-9. doi: 10.1161/ATVBAHA.111.238642. Epub 2011 Sep 29.

10.

Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites.

Pitman JL, Bonnet DJ, Curtiss LK, Gekakis N.

J Lipid Res. 2011 Oct;52(10):1775-86. doi: 10.1194/jlr.M017277. Epub 2011 Aug 1.

11.

Effects of chronic mental stress and atherogenic diet on the immune inflammatory environment in mouse aorta.

Marcondes MC, Zhukov V, Bradlow H, Sanchez-Alavez M, Gonzalez AS, Curtiss LK, Conti B.

Brain Behav Immun. 2011 Nov;25(8):1649-57. doi: 10.1016/j.bbi.2011.06.007. Epub 2011 Jun 22.

12.

Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma.

Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS.

Nat Struct Mol Biol. 2011 Apr;18(4):416-22. doi: 10.1038/nsmb.2028. Epub 2011 Mar 13.

13.

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Nob├ęcourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, Bonnet DJ, Curtiss LK, Barter PJ, Rye KA.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):766-72. doi: 10.1161/ATVBAHA.109.201715. Epub 2010 Jan 28.

14.

Reversing atherosclerosis?

Curtiss LK.

N Engl J Med. 2009 Mar 12;360(11):1144-6. doi: 10.1056/NEJMcibr0810383. No abstract available.

PMID:
19279347
15.

Disruption of tissue-specific fucosyltransferase VII, an enzyme necessary for selectin ligand synthesis, suppresses atherosclerosis in mice.

Gitlin JM, Homeister JW, Bulgrien J, Counselman J, Curtiss LK, Lowe JB, Boisvert WA.

Am J Pathol. 2009 Jan;174(1):343-50. doi: 10.2353/ajpath.2009.080036. Epub 2008 Dec 4.

16.

Emerging role of Toll-like receptors in atherosclerosis.

Curtiss LK, Tobias PS.

J Lipid Res. 2009 Apr;50 Suppl:S340-5. doi: 10.1194/jlr.R800056-JLR200. Epub 2008 Nov 1. Review.

17.

Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP.

Hime NJ, Black AS, Bulgrien JJ, Curtiss LK.

J Lipid Res. 2008 Oct;49(10):2113-23. doi: 10.1194/jlr.M700564-JLR200. Epub 2008 Jul 3.

18.

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events.

Mullick AE, Soldau K, Kiosses WB, Bell TA 3rd, Tobias PS, Curtiss LK.

J Exp Med. 2008 Feb 18;205(2):373-83. doi: 10.1084/jem.20071096. Epub 2008 Feb 4.

19.

The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis.

Curtiss LK, Tobias PS.

Curr Drug Targets. 2007 Dec;8(12):1230-8. Review.

PMID:
18220700
20.

TLR2 in murine atherosclerosis.

Tobias PS, Curtiss LK.

Semin Immunopathol. 2008 Feb;30(1):23-7. Epub 2007 Dec 6. Review.

PMID:
18058099
21.

Toll-like receptors in atherosclerosis.

Tobias PS, Curtiss LK.

Biochem Soc Trans. 2007 Dec;35(Pt 6):1453-5. Review.

PMID:
18031244
22.

Expression of the Lyst(beige) mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice.

Petrovan RJ, Yuan Y, Curtiss LK.

J Lipid Res. 2008 Feb;49(2):429-37. Epub 2007 Nov 2.

23.

Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.

Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK.

J Lipid Res. 2008 Jan;49(1):24-32. Epub 2007 Oct 10.

24.

DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice.

Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1095-100. Epub 2007 Feb 15.

PMID:
17303776
25.

The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA.

Diabetologia. 2007 Mar;50(3):643-53. Epub 2007 Jan 10.

PMID:
17216278
26.

Is two out of three enough for ABCG1?

Curtiss LK.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2175-7. No abstract available.

PMID:
16990560
27.

Toll-like receptors and atherosclerosis: key contributors in disease and health?

Mullick AE, Tobias PS, Curtiss LK.

Immunol Res. 2006;34(3):193-209. Review.

PMID:
16891671
28.

Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression.

Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM.

Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1572-8. Epub 2006 May 4.

PMID:
16675720
29.

Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression.

Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, Terkeltaub RA.

Am J Pathol. 2006 Apr;168(4):1385-95.

30.

Overexpression of human ApoAI transgene provides long-term atheroprotection in LDL receptor-deficient mice.

Valenta DT, Bulgrien JJ, Banka CL, Curtiss LK.

Atherosclerosis. 2006 Dec;189(2):255-63. Epub 2006 Jan 19.

PMID:
16423356
31.

Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size.

Boisvert WA, Rose DM, Boullier A, Quehenberger O, Sydlaske A, Johnson KA, Curtiss LK, Terkeltaub R.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):563-9. Epub 2006 Jan 12.

PMID:
16410462
32.

Atherosclerosis in mice is not affected by a reduction in tissue factor expression.

Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, Shen Y, Day S, Huang Y, Eitzman DT, Boisvert WA, Curtiss LK, Fay WP, Mackman N.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):555-62. Epub 2005 Dec 29.

PMID:
16385085
33.

What is so special about apolipoprotein AI in reverse cholesterol transport?

Curtiss LK, Valenta DT, Hime NJ, Rye KA.

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):12-9. Epub 2005 Nov 3. Review.

PMID:
16269660
34.

Modulation of atherosclerosis in mice by Toll-like receptor 2.

Mullick AE, Tobias PS, Curtiss LK.

J Clin Invest. 2005 Nov;115(11):3149-56. Epub 2005 Oct 6.

35.

Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice.

Bradshaw G, Gutierrez A, Miyake JH, Davis KR, Li AC, Glass CK, Curtiss LK, Davis RA.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11029-34. Epub 2005 Jul 25.

36.

Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I.

Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA.

J Lipid Res. 2005 May;46(5):896-903. Epub 2005 Feb 1.

37.

High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.

Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, Tsimikas S, Curtiss LK, Marcovina SM, Taylor JM, Lawn RM, Innerarity TL, Pitas RE.

J Lipid Res. 2005 Apr;46(4):769-78. Epub 2005 Jan 16.

38.
39.

Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3).

Wiedmer T, Zhao J, Li L, Zhou Q, Hevener A, Olefsky JM, Curtiss LK, Sims PJ.

Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13296-301. Epub 2004 Aug 24.

40.

IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL.

J Clin Invest. 2004 Aug;114(3):427-37.

41.

Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.

Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH.

Circulation. 2004 Jun 29;109(25):3164-70. Epub 2004 Jun 7.

PMID:
15184281
42.

Participation of macrophages in atherosclerotic lesion morphology in LDLr-/- mice.

Schiller NK, Black AS, Bradshaw GP, Bonnet DJ, Curtiss LK.

J Lipid Res. 2004 Aug;45(8):1398-409. Epub 2004 Jun 1.

43.

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta.

Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK.

Science. 2003 Oct 17;302(5644):453-7. Epub 2003 Sep 11. Erratum in: Science. 2003 Nov 14;302(5648):1153.

44.

Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells.

Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, Ehnholm C, Curtiss LK.

J Lipid Res. 2003 Aug;44(8):1453-61. Epub 2003 May 1.

45.

Identification and properties of glycated monoclonal IgA that affect the fructosamine assay.

Fujita K, Curtiss LK, Sakurabayashi I, Kameko F, Okumura N, Terasawa F, Tozuka M, Katsuyama T.

Clin Chem. 2003 May;49(5):805-8. No abstract available.

46.

Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation.

Rye KA, Wee K, Curtiss LK, Bonnet DJ, Barter PJ.

J Biol Chem. 2003 Jun 20;278(25):22530-6. Epub 2003 Apr 10.

47.

Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling.

Rye KA, Duong M, Psaltis MK, Curtiss LK, Bonnet DJ, Stocker R, Barter PJ.

Biochemistry. 2002 Oct 15;41(41):12538-45.

PMID:
12369845
48.

Inflammation in atherosclerosis: lesion formation in LDL receptor-deficient mice with perforin and Lyst(beige) mutations.

Schiller NK, Boisvert WA, Curtiss LK.

Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1341-6.

PMID:
12171798
49.

Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes.

Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA.

Circ Res. 2002 May 31;90(10):1064-71.

PMID:
12039795
50.

Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta.

Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, Tontonoz P, Edwards PA.

J Biol Chem. 2002 Aug 30;277(35):31900-8. Epub 2002 May 24.

Supplemental Content

Loading ...
Support Center